Amikacin and cephalothin: empiric regimen for granulocytopenic cancer patients.
Amikacin (15 mg/kg per day) was used in combination with cephalothin (7 g/m(2) per day) as an empiric regimen for de novo febrile (>101 degrees F [38.3 degrees C]) episodes in 93 granulocytopenic (<1,000/mm(3)) cancer patients. Both drugs were given intravenously in four equal doses every 6 h. The response rate for all documented infections was 83%, including 11 of 17 (65%) bacteremias. Escherichia coli (14 cases) was the most common pathogen, whereas Pseudomonas aeruginosa (2 cases) caused fewer infections. Mean amikacin serum levels were 8.7 mug/ml at 1 h and 2.2 mug/ml at 5 h. Failure of bone marrow recovery in association with a bacteremia was a bad prognostic sign (only two of eight improving). Ototoxicity occurred in two (2%) patients, whereas presumed antibiotic-induced nephrotoxicity developed in six (7%) patients. Surveillance cultures (nose, gums axilla, and rectum) of all hospitalized patients revealed no significant change in the incidence of amikacin resistance. The combination of amikacin and cephalothin in this dose and schedule was safe and efficacious in these granulocytopenic patients.
D000328:Adult; D000380:Agranulocytosis / Q000188:drug therapy*; D000583:Amikacin / Q000627:therapeutic use* / Q000633:toxicity; D002512:Cephalothin / Q000627:therapeutic use* / Q000633:toxicity; D004359:Drug Therapy, Combination; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D006801:Humans; D007612:Kanamycin / Q000031:analogs & derivatives*; D008297:Male; D009369:Neoplasms / Q000150:complications*; D011552:Pseudomonas Infections / Q000188:drug therapy
D007612:Kanamycin; D000583:Amikacin; D002512:Cephalothin